METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with prostate cancer that has spread and has neuroendocrine features. The drug targets and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New scan spots hidden prostate cancer that standard tests miss
Diagnosis Recruiting nowThis study tests whether a special PET scan using 18F-fluciclovine can better detect advanced prostate cancer that doesn't show up well on standard scans. It involves 30 people with metastatic prostate cancer that either has low PSMA levels or neuroendocrine features. Participant…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 14, 2026 12:03 UTC